{"id":"https://openalex.org/W7204012293","doi":"https://doi.org/10.17615/7hcm-fg22","title":"4-Anilinoquinazoline carbamate derivatization as a platform for prodrug design and localized drug delivery.","display_name":"4-Anilinoquinazoline carbamate derivatization as a platform for prodrug design and localized drug delivery.","publication_year":2026,"publication_date":"2026-08-22","ids":{"openalex":"https://openalex.org/W7204012293","doi":"https://doi.org/10.17615/7hcm-fg22"},"language":"en","primary_location":{"id":"doi:10.17615/7hcm-fg22","doi":"https://doi.org/10.17615/7hcm-fg22","is_oa":true,"landing_page_url":"https://doi.org/10.17615/7hcm-fg22","pdf_url":null,"source":{"id":"https://openalex.org/S7407051488","display_name":"UNC Libraries","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"article-journal"},"volume":null,"type":"article","indexed_in":["datacite"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://doi.org/10.17615/7hcm-fg22","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5043471149","display_name":"M. Alejandro Valdes-Pena","orcid":"https://orcid.org/0000-0002-5705-1912","observed_orcids":["https://orcid.org/0000-0002-5705-1912"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Valdes-Pena, M Alejandro","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5134455296","display_name":"Coleman D. Walker","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Walker, Coleman D","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5118702577","display_name":"Osman Gani","orcid":"https://orcid.org/0009-0000-0515-2781","observed_orcids":["https://orcid.org/0009-0000-0515-2781"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gani, Osman","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038733221","display_name":"Audrey G. Fikes","orcid":"https://orcid.org/0000-0003-4034-6260","observed_orcids":["https://orcid.org/0000-0003-4034-6260"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Fikes, Audrey","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077561488","display_name":"Micah Mallory","orcid":"https://orcid.org/0000-0001-5905-102X","observed_orcids":["https://orcid.org/0000-0001-5905-102X"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mallory, Micah","raw_affiliation_strings":["University of North Carolina at Chapel Hill"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of North Carolina at Chapel Hill","institution_ids":["https://openalex.org/I114027177"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058260183","display_name":"Yevgeny Brudno","orcid":"https://orcid.org/0000-0003-2963-3293","observed_orcids":["https://orcid.org/0000-0003-2963-3293"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brudno, Yevgeny","raw_affiliation_strings":["University of North Carolina at Chapel Hill"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of North Carolina at Chapel Hill","institution_ids":["https://openalex.org/I114027177"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000627767","display_name":"Christopher R. M. Asquith","orcid":"https://orcid.org/0000-0001-5871-3458","observed_orcids":["https://orcid.org/0000-0001-5871-3458"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Asquith, Christopher R M","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066409069","display_name":"Tuomo Laitinen","orcid":"https://orcid.org/0000-0003-1539-2142","observed_orcids":["https://orcid.org/0000-0003-1539-2142"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Laitinen, Tuomo","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070964859","display_name":"Joshua G. Pierce","orcid":"https://orcid.org/0000-0001-9194-3765","observed_orcids":["https://orcid.org/0000-0001-9194-3765"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Pierce, Joshua G","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5002402010","display_name":"Mabel Barreiro Carpio","orcid":"https://orcid.org/0000-0002-2226-2664","observed_orcids":["https://orcid.org/0000-0002-2226-2664"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Carpio, Mabel Barreiro","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.48086849,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12318","display_name":"Quinazolinone synthesis and applications","score":0.5957000255584717,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},"topics":[{"id":"https://openalex.org/T12318","display_name":"Quinazolinone synthesis and applications","score":0.5957000255584717,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10274","display_name":"Heterocyclic Compound Synthesis and Bioactivity","score":0.19589999318122864,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.03550000116229057,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/4-anilinoquinazolines","display_name":"4-anilinoquinazolines","score":0.9509999752044678},{"id":"https://openalex.org/keywords/prodrug-design","display_name":"prodrug design","score":0.8220000267028809},{"id":"https://openalex.org/keywords/egfr-tyrosine-kinase-inhibitors","display_name":"EGFR tyrosine kinase inhibitors","score":0.9010000228881836},{"id":"https://openalex.org/keywords/alginate-hydrogel","display_name":"alginate hydrogel","score":0.7770000100135803},{"id":"https://openalex.org/keywords/local-drug-delivery","display_name":"local drug delivery","score":0.7919999957084656},{"id":"https://openalex.org/keywords/ph-responsive-drug-release","display_name":"pH-responsive drug release","score":0.7590000033378601},{"id":"https://openalex.org/keywords/tumor-microenvironment","display_name":"tumor microenvironment","score":0.7089999914169312},{"id":"https://openalex.org/keywords/target-engagement","display_name":"target engagement","score":0.5220000147819519},{"id":"https://openalex.org/keywords/gefitinib","display_name":"gefitinib","score":0.7599999904632568},{"id":"https://openalex.org/keywords/lapatinib","display_name":"lapatinib","score":0.8420000076293945},{"id":"https://openalex.org/keywords/erlotinib","display_name":"erlotinib","score":0.9079999923706055},{"id":"https://openalex.org/keywords/afatinib","display_name":"afatinib","score":0.777999997138977},{"id":"https://openalex.org/keywords/molecular-dynamics-simulation","display_name":"molecular dynamics simulation","score":0.41100001335144043},{"id":"https://openalex.org/keywords/protein-ligand-binding","display_name":"protein-ligand binding","score":0.7179999947547913}],"concepts":[{"id":"https://openalex.org/C108215921","wikidata":"https://www.wikidata.org/wiki/Q603741","display_name":"Prodrug","level":2,"score":0.9114000201225281},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.8263999819755554},{"id":"https://openalex.org/C2776923573","wikidata":"https://www.wikidata.org/wiki/Q2294884","display_name":"Derivatization","level":3,"score":0.7148000001907349},{"id":"https://openalex.org/C2779303437","wikidata":"https://www.wikidata.org/wiki/Q422899","display_name":"Carbamate","level":2,"score":0.6180999875068665},{"id":"https://openalex.org/C2781326480","wikidata":"https://www.wikidata.org/wiki/Q7041501","display_name":"Nitroreductase","level":3,"score":0.5992000102996826},{"id":"https://openalex.org/C21951064","wikidata":"https://www.wikidata.org/wiki/Q899212","display_name":"Combinatorial chemistry","level":1,"score":0.5665000081062317},{"id":"https://openalex.org/C2780557392","wikidata":"https://www.wikidata.org/wiki/Q523796","display_name":"Linker","level":2,"score":0.5519999861717224},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.5411999821662903},{"id":"https://openalex.org/C2780784506","wikidata":"https://www.wikidata.org/wiki/Q4859711","display_name":"Deamidation","level":3,"score":0.4244000017642975},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.39010000228881836},{"id":"https://openalex.org/C94412978","wikidata":"https://www.wikidata.org/wiki/Q103135","display_name":"Hydrolysis","level":2,"score":0.350600004196167},{"id":"https://openalex.org/C2779820397","wikidata":"https://www.wikidata.org/wiki/Q1392806","display_name":"Drug delivery","level":2,"score":0.34610000252723694},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.3386000096797943},{"id":"https://openalex.org/C71240020","wikidata":"https://www.wikidata.org/wiki/Q186011","display_name":"Stereochemistry","level":1,"score":0.3228999972343445},{"id":"https://openalex.org/C74187038","wikidata":"https://www.wikidata.org/wiki/Q1418791","display_name":"Drug discovery","level":2,"score":0.31540000438690186},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.3151000142097473},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.31200000643730164},{"id":"https://openalex.org/C53105671","wikidata":"https://www.wikidata.org/wiki/Q14777816","display_name":"Rational design","level":2,"score":0.3102000057697296},{"id":"https://openalex.org/C2777752112","wikidata":"https://www.wikidata.org/wiki/Q903238","display_name":"Lead compound","level":3,"score":0.3046000003814697},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.30399999022483826},{"id":"https://openalex.org/C2780071497","wikidata":"https://www.wikidata.org/wiki/Q2746231","display_name":"Chloroformate","level":2,"score":0.30140000581741333},{"id":"https://openalex.org/C43617362","wikidata":"https://www.wikidata.org/wiki/Q170050","display_name":"Chromatography","level":1,"score":0.3012999892234802},{"id":"https://openalex.org/C201399114","wikidata":"https://www.wikidata.org/wiki/Q898401","display_name":"Lipophilicity","level":2,"score":0.2842000126838684},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.2825999855995178},{"id":"https://openalex.org/C85196483","wikidata":"https://www.wikidata.org/wiki/Q6545857","display_name":"Ligand binding assay","level":3,"score":0.26809999346733093},{"id":"https://openalex.org/C2778484023","wikidata":"https://www.wikidata.org/wiki/Q415190","display_name":"Benzimidazole","level":2,"score":0.2635999917984009},{"id":"https://openalex.org/C2776793103","wikidata":"https://www.wikidata.org/wiki/Q419834","display_name":"Primaquine","level":4,"score":0.26100000739097595},{"id":"https://openalex.org/C2776120743","wikidata":"https://www.wikidata.org/wiki/Q3271540","display_name":"Mechanism of action","level":3,"score":0.2565999925136566},{"id":"https://openalex.org/C207464780","wikidata":"https://www.wikidata.org/wiki/Q7209103","display_name":"Polar surface area","level":3,"score":0.25459998846054077}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.17615/7hcm-fg22","doi":"https://doi.org/10.17615/7hcm-fg22","is_oa":true,"landing_page_url":"https://doi.org/10.17615/7hcm-fg22","pdf_url":null,"source":{"id":"https://openalex.org/S7407051488","display_name":"UNC Libraries","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"article-journal"}],"best_oa_location":{"id":"doi:10.17615/7hcm-fg22","doi":"https://doi.org/10.17615/7hcm-fg22","is_oa":true,"landing_page_url":"https://doi.org/10.17615/7hcm-fg22","pdf_url":null,"source":{"id":"https://openalex.org/S7407051488","display_name":"UNC Libraries","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"article-journal"},"sustainable_development_goals":[{"score":0.8371999859809875,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1996023624","https://openalex.org/W2527841560","https://openalex.org/W4390638271","https://openalex.org/W4206490358","https://openalex.org/W2075498563","https://openalex.org/W2588428981","https://openalex.org/W2339849530","https://openalex.org/W950873022","https://openalex.org/W2734066598","https://openalex.org/W1185762171"],"abstract_inverted_index":{"Tyrosine":[0],"kinase":[1,159],"inhibitors":[2],"(TKI)":[3],"based":[4],"on":[5],"the":[6,22,43,143],"4-anilinoquinazoline":[7],"(AQ)":[8],"scaffold,":[9],"including":[10],"gefitinib,":[11],"lapatinib,":[12],"erlotinib,":[13,64],"etc.,":[14],"are":[15],"limited":[16],"clinically":[17],"by":[18],"undesired":[19],"inhibition":[20],"of":[21,42,61],"Epidermal":[23],"Growth":[24],"Factor":[25],"Receptor":[26],"(EGFR)":[27],"in":[28,100,173],"healthy":[29],"tissues,":[30],"causing":[31],"toxicities":[32],"and":[33,54,118,136,149,157,177,200,210],"narrow":[34],"therapeutic":[35],"windows.":[36],"Here,":[37],"we":[38,107],"evaluate":[39],"carbamate":[40,115,190],"masking":[41],"AQ":[44,189],"hinge":[45],"nitrogen":[46],"as":[47,192],"a":[48,59,70,193],"scaffold-centered":[49],"strategy":[50],"to":[51,141,166,183],"modulate":[52],"exposure":[53],"enable":[55],"controlled":[56],"activation":[57],"across":[58],"panel":[60],"EGFR-TKIs":[62],"(PD153035,":[63],"afatinib,":[65],"lapatinib).":[66],"We":[67],"first":[68],"explored":[69],"\u03b2-eliminative":[71],"sulfone":[72],"linker":[73],"design":[74,199,203],"for":[75,97,162,196],"localized":[76],"release":[77,88],"from":[78],"alginate":[79],"hydrogels.":[80],"Hydrolysis":[81],"profiling":[82],"revealed":[83],"that":[84],"efficient":[85,138],"parent":[86,144],"drug":[87],"occurred":[89],"only":[90],"at":[91],"basic":[92],"pH,":[93],"defining":[94],"key":[95],"constraints":[96],"depot":[98],"formulations":[99],"mildly":[101],"acidic":[102],"tumor":[103],"microenvironments.":[104],"In":[105],"parallel,":[106],"developed":[108],"nitroreductase":[109],"(NTR)-activatable":[110],"AQ-TKI":[111],"prodrugs.":[112],"The":[113],"nitroimidazole":[114],"increased":[116],"polarity":[117],"adjusted":[119],"solubility":[120],"while":[121],"maintaining":[122],"overall":[123],"drug-like":[124],"SwissADME":[125],"profiles.":[126],"All":[127],"prodrugs":[128,164],"were":[129],"chemically":[130],"stable":[131],"under":[132],"physiologically":[133],"relevant":[134],"conditions":[135],"underwent":[137],"NTR-dependent":[139],"uncaging":[140],"regenerate":[142],"TKIs.":[145],"Molecular":[146],"dynamics":[147],"simulations":[148],"Boltz-2":[150],"protein-ligand":[151],"affinity":[152],"predictions":[153],"showed":[154],"weakened":[155],"binding":[156],"reduced":[158],"target":[160,211],"space":[161],"intact":[163],"relative":[165],"parents,":[167],"consistent":[168],"with":[169],"higher":[170],"IC\u2085\u2080":[171],"values":[172],"cell-free":[174],"EGFR":[175],"assays":[176],"supporting":[178],"attenuated":[179],"basal":[180],"activity":[181],"prior":[182],"activation.":[184],"Together,":[185],"these":[186],"results":[187],"establish":[188],"derivatization":[191],"generalizable":[194],"platform":[195],"EGFR-TKI":[197],"prodrug":[198],"provide":[201],"quantitative":[202],"rules":[204],"linking":[205],"scaffold":[206],"masking,":[207],"stability,":[208],"activation,":[209],"engagement.":[212]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2026-08-23T00:00:00"}